Spyre Therapeutics (SYRE) News Today $15.25 -0.30 (-1.93%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$14.84 -0.41 (-2.72%) As of 05/30/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYRE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Wellington Management Group LLP Has $37.35 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Wellington Management Group LLP boosted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 6.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,604,508 shares of the company's stock afJune 1 at 5:14 AM | marketbeat.comMillennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE)Millennium Management LLC acquired a new stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 167,804 shares of the company's stMay 31 at 3:37 AM | marketbeat.comAnalysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $53.40May 31 at 2:07 AM | americanbankingnews.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Voloridge Investment Management LLCVoloridge Investment Management LLC trimmed its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 26.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 115,470 shares of the company'sMay 29 at 4:29 AM | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has received an average recommendation of "Buy" from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendatMay 29 at 3:20 AM | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 28, 2025 | prnewswire.comBNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)BNP Paribas Financial Markets acquired a new stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,784 shares of thMay 27, 2025 | marketbeat.comWoodline Partners LP Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Woodline Partners LP grew its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 33.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 352,680 shares of the company's stock after acquiring anMay 25, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust CorpNorthern Trust Corp grew its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 348,983 shares of the company's stock after acquiring an additionalMay 21, 2025 | marketbeat.comRTW Investments LP Raises Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)RTW Investments LP increased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,621,996 shares of the company's stock after buying an additional 363,636 shMay 18, 2025 | marketbeat.comPolar Capital Holdings Plc Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Polar Capital Holdings Plc raised its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 50.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 750,000 shares of the companMay 18, 2025 | marketbeat.comProsight Management LP Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Prosight Management LP bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the company's stock, valued at approximately $May 17, 2025 | marketbeat.comJanus Henderson Group PLC Buys 336,209 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Janus Henderson Group PLC grew its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 30.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,456,740 shares of the company's stock after acquMay 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Paradigm Biocapital Advisors LP raised its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 20.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,527,205May 16, 2025 | marketbeat.comJefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Jefferies Financial Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 167.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,216,954 shares of the companMay 13, 2025 | marketbeat.comFirst Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)First Trust Advisors LP acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 23,550 shares of the company's stock, valued at approximately $548,000. A nMay 12, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)May 10, 2025 | theglobeandmail.comDeerfield Management Company L.P. Series C Purchases Shares of 450,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)Deerfield Management Company L.P. Series C bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 450,000 shares of the company's stock, valued atMay 10, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Holdings Raised by Driehaus Capital Management LLCDriehaus Capital Management LLC increased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 308.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,803,655 shares of the companMay 10, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 9, 2025 | finanznachrichten.deDeep Track Capital LP Lowers Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Deep Track Capital LP lowered its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 78.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 219,015 shares of the company's stock afMay 9, 2025 | marketbeat.comSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comBraidwell LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Braidwell LP boosted its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 17.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,578,404 shares of the company's stock after buying an additional 388May 8, 2025 | marketbeat.comBlackstone Inc. Acquires 156,206 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Blackstone Inc. lifted its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 53.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 449,201 shares of the company's stock after buying an additional 156,206May 8, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 5.8% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.8% - What's Next?May 7, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday.May 7, 2025 | marketbeat.comInvesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Invesco Ltd. cut its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 85.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,663 shares of the company's stock after selling 118,195 shares during the periMay 6, 2025 | marketbeat.comSpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001May 5, 2025 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from AnalystsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given an average rating of "Buy" by the ten brokerages that are currently covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendationMay 5, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 77,323 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Price T Rowe Associates Inc. MD grew its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 18.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 506,450 shares of the company'May 5, 2025 | marketbeat.comBoxer Capital Management LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Boxer Capital Management LLC purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 466,680 shares of the company's stock, valuedMay 4, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO), Spyre Therapeutics (SYRE) and Herbalife (HLF)May 3, 2025 | theglobeandmail.comSpyre Therapeutics (SYRE) to Release Earnings on ThursdaySpyre Therapeutics (NASDAQ:SYRE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-spyre-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 2, 2025 | prnewswire.comBarclays PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Barclays PLC boosted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 123,071 shares of the company's stock afterMay 2, 2025 | marketbeat.comSoros Fund Management LLC Acquires 105,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Soros Fund Management LLC increased its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 72.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 250,000 shares of the company's stock after pMay 1, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Emerald Mutual Fund Advisers TrustEmerald Mutual Fund Advisers Trust raised its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 52.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 386,384 shares of the company's stock after purchasinMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Adage Capital Partners GP L.L.C. reduced its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,030,000 shares of the company's stoApril 28, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Trading Down 3.6% - What's Next?April 24, 2025 | marketbeat.comCapital World Investors Invests $8.81 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Capital World Investors purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 378,573 shares of the company's stock, valued at approxApril 24, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Still a Buy?Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 6.3% - What's Next?April 23, 2025 | marketbeat.comB Group Inc. Buys Shares of 50,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)B Group Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company's stock, valuApril 23, 2025 | marketbeat.comGeode Capital Management LLC Buys 75,081 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Geode Capital Management LLC raised its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 966,129 shares of the company's stock after purchasing anApril 21, 2025 | marketbeat.comAffinity Asset Advisors LLC Purchases 325,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Affinity Asset Advisors LLC increased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 65.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 824,328 shares of theApril 17, 2025 | marketbeat.comFmr LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Fmr LLC lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 15.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,801,266 shares of the company's stock after buying an additional 1,177,385 shaApril 15, 2025 | marketbeat.comF M Investments LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)F M Investments LLC purchased a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 48,806 shares of the company's stock, valued at approximately $1,136,000. F M Investments LLCApril 14, 2025 | marketbeat.comVanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Vanguard Group Inc. raised its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 13.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,846,473 shares of the company's stock after acquApril 13, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for SYRE Q1 Earnings?Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Spyre Therapeutics in a research note issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of (April 12, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at Leerink PartnrsLeerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday.April 11, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Leerink PartnersLeerink Partners assumed coverage on Spyre Therapeutics in a report on Tuesday. They set an "outperform" rating and a $45.00 price objective for the company.April 10, 2025 | marketbeat.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼1.290.88▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼84▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News Today ACLX News Today SWTX News Today ZLAB News Today RARE News Today ALVO News Today VKTX News Today CPRX News Today MTSR News Today MOR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
